NEW YORK--(BUSINESS WIRE)--Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS):
Listing market: NYSE Euronext Paris
ISIN code: FR0010425595
| Date |
Total number of shares in the capital |
Total number of voting |
||
| 01/31/2018 | 35,959,462 | 41,114,862 |
About Cellectis
Cellectis is a clinical-stage
biopharmaceutical company focused on developing a new generation of
cancer immunotherapies based on gene-edited T-cells (UCART). By
capitalizing on its 18 years of expertise in gene editing – built on its
flagship TALEN® technology and pioneering electroporation system
PulseAgile – Cellectis uses the power of the immune system to target and
eradicate cancer cells.
Using its life-science-focused, pioneering genome engineering
technologies, Cellectis’ goal is to create innovative products in
multiple fields and with various target markets.
Cellectis is
listed on the Nasdaq market (ticker: CLLS) and on Euronext Growth
(ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com
Talking about gene editing? We do it. TALEN® is a registered trademark owned by the Cellectis Group.
Disclaimer
This press release contains “forward-looking”
statements that are based on our management’s current expectations and
assumptions and on information currently available to management.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results,
performance or achievements to be materially different from any future
results, performance or achievements expressed or implied by the
forward-looking statements. Further information on the risks factors
that may affect company business and financial performance, is included
in filings Cellectis makes with the Security Exchange Commission from
time to time and its financial reports. Except as required by law, we
assume no obligation to update these forward-looking statements
publicly, or to update the reasons actual results could differ
materially from those anticipated in the forward-looking statements,
even if new information becomes available in the future.
###
